0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > ALCAM

ALCAM

Brief Information

Name:Activated leukocyte cell adhesion molecule
Target Synonym:CD166 antigen,Activated leukocyte cell adhesion molecule,CD166,ALCAM,MEMD,Activated Leucocyte Cell Adhesion Molecule,Activated-Leukocyte Cell Adhesion Molecule
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CD6-H5259 Human Human ALCAM Protein, Fc Tag
CD6-H5259-structure
CD6-H5259-sds
CD6-H5228 Human Human ALCAM Protein, His Tag
CD6-H5228-structure
CD6-H5228-sds

Synonym Name

CD166,ALCAM,CD6L,KG-CAM,MEMD

Background

CD166 antigen is a 100-105 kD typeI transmembrane glycoprotein that is a member of the immunoglobulin superfamily of proteins, which is also known as Activated leukocyte cell adhesion molecule (ALCAM) in human, SC-1/DM-GRASP/BEN in the chicken, and KG-CAM in the rat. CD166 is a cell adhesion molecule that binds to CD6. CD166 involved in neurite extension by neurons via heterophilic and homophilic interactions.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CD166 probody drug conjugate (CytomX Therapeutics/ImmunoGen) CX-2009 Phase 2 Clinical Immunogen Inc, Cytomx Therapeutics Ovarian Neoplasms; Head and Neck Neoplasms; Biliary Tract Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop